Quanterix (NASDAQ:QTRX) Releases Earnings Results, Misses Expectations By $0.11 EPS

Quanterix (NASDAQ:QTRX) announced its quarterly earnings data on Monday. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.11), Zacks reports. The firm had revenue of $41.40 million for the quarter, compared to the consensus estimate of $37.95 million. Quanterix had a negative net margin of 73.47% and a negative return on equity of 21.34%.

Here are the key takeaways from Quanterix’s conference call:

• Quanterix ended Q4 with a strong liquidity and cost profile — $122M in cash, no debt, has realized $74M of an $85M synergy target and expects to reach full synergies by end of Q1, with a plan to achieve cash-flow breakeven in H2 2026 and ~ $100M cash at year-end.
• Underlying demand weakness persists — Q4 total revenue was $43.9M (+25% YoY) but organic revenue declined ~22% (Simoa -22%, Spatial -23%), academic customers were ~55% of mix and pharma revenue fell 21%, and 2026 guidance of $169–174M assumes no market improvement.
• Diagnostics progress for LucentAD Complete is a key commercial catalyst — CMS set a $897 reimbursement rate, Quanterix submitted a 510(k) in Jan 2026 and expects FDA clearance in ~6–9 months, while clinical utility studies and payer engagement are underway.
• New CEO Everett Cunningham brings commercial-scale experience and is prioritizing growth and ROI — management expects a steady cadence of assay launches in 2026, is running early access for the higher-plex Simoa One platform, and will prioritize investments to drive diagnostics and larger pharma Accelerator projects.

Quanterix Stock Down 3.4%

QTRX stock opened at $6.33 on Tuesday. Quanterix has a twelve month low of $4.05 and a twelve month high of $8.77. The stock has a market capitalization of $295.67 million, a price-to-earnings ratio of -2.72 and a beta of 1.05. The firm’s fifty day simple moving average is $6.51 and its two-hundred day simple moving average is $6.00.

Analysts Set New Price Targets

Several analysts recently issued reports on QTRX shares. Canaccord Genuity Group increased their target price on Quanterix from $5.00 to $8.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quanterix currently has an average rating of “Hold” and an average target price of $11.33.

Institutional Trading of Quanterix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in Quanterix in the fourth quarter worth about $27,000. Quarry LP raised its holdings in shares of Quanterix by 277,300.0% in the third quarter. Quarry LP now owns 5,548 shares of the company’s stock worth $30,000 after buying an additional 5,546 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Quanterix in the fourth quarter worth approximately $75,000. HUB Investment Partners LLC bought a new stake in shares of Quanterix during the 2nd quarter worth approximately $81,000. Finally, HRT Financial LP purchased a new position in Quanterix during the 4th quarter valued at $82,000. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.